Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Radiological Society of North America | OTHER |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Investigators hope to learn more about how to use computed tomography (CT) scans to measure blood flow in lung tumors and how it may change in response to treatment. This measurement technique is called computed tomography perfusion (CTP). CT scanners use X-rays to produce 3-dimensional images of the body.
Currently, doctors determine the response to treatment by measuring the size of the tumor. Investigators are trying to find out if measuring the blood flow in the tumor is equal to or better than measuring the size of the tumor.
This is an experimental study of CT perfusion (CTP) imaging in subjects with non-small cell lung cancer. The objectives of this study are to demonstrate the feasibility of CT blood flow measurements in lung cancer, to develop a foundation for the use of CT blood flow measurements in lung cancer to assess the response to treatment, and to develop an optimized CTP imaging protocol for evaluating blood flow in solid body tumors. In this study, tumor blood flow will be evaluated at baseline and follow-up routine CT examinations of patients with non-small cell lung cancer, and the response of tumor blood flow will be recorded as a secondary endpoint. This research study will entail two study visits - one required and one optional - which will coincide with regularly scheduled standard of care CT scans.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Variability of measurements | variability of CTP measurements will be determined by repeating the CTP examination, and comparing the resultant blood flow estimates | ||
| Treatment induced effects | The magnitude of treatment induced effects will be assessed by comparing tumor blood flow estimates before and after treatment |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Yield of conducting CTP studies | Yield is determined as the percentage of assessable CTP studies, relative to all performed studies | 2 years |
| Measure | Description | Time Frame |
|---|---|---|
| Variability of CTP measurements | Variability will be determined from two consecutively acquired CTP examinations, and repeated analyses of the same studies | 2 years |
| Magnitude of treatment induced changes in tumor blood flow |
Not provided
Inclusion Criteria:
adult patients with non small cell lung cancer who receive, or are considered for, systemic therapy
Exclusion Criteria:
renal failure pregnancy known contrast allergy
-
Not provided
Not provided
Not provided
patients with non small cell lung cancer who are planned to receive systemic therapy
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Friedrich Knollmann, MD, PhD | Univeristy of California, Davis | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of California, Davis Medical Center | Sacramento | California | 95817 | United States |
Not provided
| ID | Term |
|---|---|
| D002289 | Carcinoma, Non-Small-Cell Lung |
| D008175 | Lung Neoplasms |
| ID | Term |
|---|---|
| D002283 | Carcinoma, Bronchogenic |
| D001984 | Bronchial Neoplasms |
| D012142 | Respiratory Tract Neoplasms |
| D013899 | Thoracic Neoplasms |
Not provided
Not provided
Not provided
Not provided
Not provided
The magnitude of treatment induced changes in blood flow will be determined from comparisons of bloodflow before and after treatment
| 2 years |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |